Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Optimal management therapy for Pseudomonas aeruginosa *

Optimal management therapy for Pseudomonas aeruginosa * Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* Jose Garnacho-Montero, MD, PhD; Marcio Sa-Borges, MD; Jordi Sole-Violan, MD; Fernando Barcenilla, MD; Ana Escoresca-Ortega, MD; Miriam Ochoa, MD; Aurelio Cayuela, MD, PhD, MPH; Jordi Rello, MD, PhD Objective: To evaluate whether one antibiotic achieves equal definitive regimen did not influence mortality, length of stay, outcomes compared with combination antibiotic therapy in pa- development of resistance to the definitive treatment, or appear- tients with Pseudomonas aeruginosa ventilator-associated pneu- ance of recurrences. Inappropriate empirical therapy was asso- monia. ciated with increased mortality (adjusted hazard ratio 1.85; 95% Design: A retrospective, multicenter, observational, cohort confidence interval 1.07–3.10; p  .02) in a Cox proportional study. hazard regression analysis, after adjustment for disease severity, Setting: Five intensive care units in Spanish university hospi- but not effective monotherapy (adjusted hazard ratio 0.90; 95% tals. confidence interval 0.50 –1.63; p  .73) compared with effective Patients: Adult patients identified to have monomicrobial epi- combination therapy (adjusted hazard ratio 1). The other two sodes of ventilator-associated pneumonia with significant quan- variables also independently associated with mortality were age titative respiratory cultures for P. aeruginosa. (adjusted hazard ratio http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Critical Care Medicine Wolters Kluwer Health

Optimal management therapy for Pseudomonas aeruginosa *

Rello, Jordi
Critical Care Medicine , Volume 35 (8) – Aug 1, 2007
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/optimal-management-therapy-for-pseudomonas-aeruginosa-ast-jGyQr9RnIs

References (33)

ISSN
0090-3493
eISSN
1530-0293
DOI
10.1097/01.CCM.0000275389.31974.22
pmid
17581492
Publisher site
See Article on Publisher Site

Abstract

Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy* Jose Garnacho-Montero, MD, PhD; Marcio Sa-Borges, MD; Jordi Sole-Violan, MD; Fernando Barcenilla, MD; Ana Escoresca-Ortega, MD; Miriam Ochoa, MD; Aurelio Cayuela, MD, PhD, MPH; Jordi Rello, MD, PhD Objective: To evaluate whether one antibiotic achieves equal definitive regimen did not influence mortality, length of stay, outcomes compared with combination antibiotic therapy in pa- development of resistance to the definitive treatment, or appear- tients with Pseudomonas aeruginosa ventilator-associated pneu- ance of recurrences. Inappropriate empirical therapy was asso- monia. ciated with increased mortality (adjusted hazard ratio 1.85; 95% Design: A retrospective, multicenter, observational, cohort confidence interval 1.07–3.10; p  .02) in a Cox proportional study. hazard regression analysis, after adjustment for disease severity, Setting: Five intensive care units in Spanish university hospi- but not effective monotherapy (adjusted hazard ratio 0.90; 95% tals. confidence interval 0.50 –1.63; p  .73) compared with effective Patients: Adult patients identified to have monomicrobial epi- combination therapy (adjusted hazard ratio 1). The other two sodes of ventilator-associated pneumonia with significant quan- variables also independently associated with mortality were age titative respiratory cultures for P. aeruginosa. (adjusted hazard ratio

Journal

Critical Care Medicine – Wolters Kluwer Health

Published: Aug 1, 2007

There are no references for this article.